Sartorius Ag · XETR:SRT
Sartorius — 9M 2026 Earnings Presentation
24 slides from Sartorius's earnings presentation, Oct 22, 2026
Slide 1: Investor Conference Call 9M 2026 Results
Variante 02: Bild Investor Conference Call 9M 2026 Results Michael Grosse, Florian Funck, René Fáber Sartorius | Sartorius Stedim Biotech | October 22, 2026
Slide 2: Agenda
Agenda Sartorius Group 9M 2026 results | FY 2026 outlook Sartorius Stedim Biotech Group 9M 2026 results | FY 2026 outlook Questions & Answers 2
Slide 3: Continued profitable growth in 9M 2026
Sartorius Group Continued profitable growth in 9M 2026 Key messages Sales revenue €2,737.2m Bioprocess Solutions Healthy recurring business and recovery in non-recurring sales (BPS) +8.1% operational growth1 Lab Products & Services Strength across the portfolio, led by Bioanalytics and AI-driven dru
Slide 4: Strong operational performance across both divisions
Sartorius Group Strong operational performance across both divisions Sartorius Group Bioprocess Solutions Lab Products & Services Sales revenue | € in millions Sales revenue | € in millions Sales revenue | € in millions +8.1%1 | +6.9% cc | +4.9% +8.1%1 | +6.8% cc | +4.6% +8.3%1 | +7.5% cc | +5.9% 2,
Slide 5: All regions with positive momentum
Sartorius Group All regions with positive momentum EMEA Americas Asia | Pacific Sales revenue | € in millions Sales revenue | € in millions Sales revenue | € in millions 6.4% cc | +6.6% +8.4%1 | +4.9% cc | 1.4% +11.0% cc | +7.1% 1,084 1,155 925 938 602 644 9M 2025 9M 2026 9M 2025 9M 2026 9M 2025 9M
Slide 6: Solid earnings growth and margin expansion
Sartorius Group Solid earnings growth and margin expansion Sartorius Group Bioprocess Solutions Lab Products & Services Ul. EBITDA & margin | Ul. EBITDA & margin | Ul. EBITDA & margin | € in millions € in millions € in millions +6.9% +7.1% +5.6% 29.7% 30.2% 31.5% 32.3% 774 828 714 21.7% 21.7% 667 10
Slide 7: Higher earnings and lower capex lift free cash flow
Sartorius Group Higher earnings and lower capex lift free cash flow Sartorius Group 9M 2025 9M 2026 ∆ in % € in millions Underlying net profit1,2 244 260 +6.7 Underlying net profit and underlying EPS increases Underlying EPS (ord.) 3.52 3.76 +6.7 with improved operating profit Underlying EPS (pref
Slide 8: Deleveraging on track; investment-grade rating commitment unchanged
Sartorius Group Deleveraging on track; investment-grade rating commitment unchanged Key financial indicators Net debt and net debt to underlying EBITDA 6.0 Sartorius Group Dec. 31, Sep. 30, 5,000 € in millions unless otherwise specified 2025 2026 5.0 4,000 4.0 Equity ratio in % 39.8 42.8 3,000 3.0 2
Slide 9: New accounting standard IFRS 18 from 2027
Sartorius Group New accounting standard IFRS 18 from 2027 Today Starting fiscal year 2027 Management-defined Recognition New EBITDA bridge Underlying EBITDA = measure unchanged EBIT + D&A + adjustments Underlying EBITDA = To be disclosed and Net result and net cash operating profit (OP) + reconciled
Slide 10: FY 2026 guidance confirmed and partially refined
Sartorius Group FY 2026 guidance confirmed and partially refined FY 2026 guidance Sartorius Group Bioprocess Solutions Lab Products & Services Sales revenue growth1 ~5% to ~9% ~6% to ~10% ~2% to ~6% thereof MATTEK acquisition ~0.3pp - ~1.5pp slightly > 21% Underlying EBITDA margin slightly > 30% sli
Slide 11: New structure strengthens One Sartorius from 2027
Sartorius Group New structure strengthens One Sartorius from 2027 CMD recap: Our strategic key initiatives Portfolio & Product Innovation Customer Centricity Operational Excellence New Operating Model New management responsibilities (as of January 1, 2027): Michael Grosse, CEO René Fáber, CPO1 Flori
Slide 12: New segments align with Sartorius corporate structure
Sartorius Group New segments align with Sartorius corporate structure Status quo New segment reporting as of 2027 Bioprocessing Research Reconciliation / Bioprocess Solutions Solutions Solutions consolidation ~€2,865 mn1 Listed Sartorius Stedim Sartorius Group ex Mainly intercompany Biotech subgroup
Slide 13: Agenda
Agenda Sartorius Group 9M 2026 results | FY 2026 outlook Sartorius Stedim Biotech Group 9M 2026 results | FY 2026 outlook Questions & Answers 13
Slide 14: Strong operational growth and robust profitability
Sartorius Stedim Biotech Group Strong operational growth and robust profitability Sales revenue Ul. EBITDA & margin € in millions € in millions 7.8%1 | +6.5% cc | +4.3% +4.8% 2,195 2,289 31.3% 31.1% 716 683 9M 2025 9M 2026 9M 2025 9M 2026 Operational development: HSD-% growth in recurring business
Slide 15: All regions with positive momentum
Sartorius Stedim Biotech Group All regions with positive momentum EMEA Americas Asia | Pacific Sales revenue | € in millions Sales revenue | € in millions Sales revenue | € in millions +6.5% cc | +6.6% +7.6%1 | +3.9% cc | 0.1% +10.6% cc | +6.5% 982 921 782 783 492 524 9M 2025 9M 2026 9M 2025 9M 2026
Slide 16: Higher earnings and lower capex lift free cash flow
Sartorius Stedim Biotech Group Higher earnings and lower capex lift free cash flow Sartorius Stedim Biotech 9M 2025 9M 2026 in % € in millions Underlying net profit1,2 320 350 +9.4 Underlying net profit and underlying EPS increases Underlying EPS 3.28 3.59 +9.4 with improved operating profit Ope
Slide 17: Lower leverage and higher equity ratio
Sartorius Stedim Biotech Group Lower leverage and higher equity ratio Key financial indicators Net debt and net debt to underlying EBITDA 4,000 6.0 Sartorius Stedim Biotech Dec. 31, Sep. 30, 5.0 € in millions unless otherwise specified 2025 2026 3,000 4.0 Equity ratio in % 51.7 54.6 2,000 3.0 2.0 1,
Slide 18: FY 2026 guidance confirmed and partially refined
Sartorius Stedim Biotech Group FY 2026 guidance confirmed and partially refined FY 2026 guidance Sartorius Stedim Biotech Group Sales revenue growth1 ~6% to ~10% Underlying EBITDA margin slightly > 31% Where we expect to land within the range Operational performance2 around the midpoint incl. custom
Slide 19: Questions & Answers
19 Questions & Answers SARTORI
Slide 20: Updated additional financial information for full-year 2026
Sartorius Group Updated additional financial information for full-year 2026 Financial information for modeling Sartorius Group Depreciation €270m to €280m Normalized financial result €165m to €175m FX effect on reported vs. cc growth around -1.1pp (vs. around -2pp before) Number of shares outstandin
Slide 21: Updated additional financial information for full-year 2026
Sartorius Stedim Biotech Group Updated additional financial information for full-year 2026 Financial information for modeling Sartorius Stedim Biotech Group Depreciation €205m to €215m Normalized financial result €105m to €115m FX effect on reported vs. cc growth around -1.2pp (prev.: around -2pp) N
Slide 22: Contacts and financial calendar
Sartorius Group Contacts and financial calendar Sven Köpsel November 17, 2026 February 23, 2027 Jefferies Global Healthcare Annual Report & FY 2026 Results Head of Corporate Communications & IR Conference, London +49.551.308.9429 April 13, 2027 sven.koepsel@sartorius.com November 24, 2026 Annual Sha
Slide 23: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee tha
Slide 24: Simplifying Progress
Simplifying Progress